Metabolife founder sentenced
This article was originally published in The Tan Sheet
Former Metabolife President Michael Ellis is sentenced to six months in prison and ordered to pay a $20,000 fine after pleading guilty to making false statements to federal regulators, according to a judgment filed June 10 in the U.S. District Court for the Southern District of California in San Diego. Ellis told FDA in 1998 that his company had never received any consumer complaints related to its ephedra-containing Metabolife 365. The weight-control supplement firm later released 13,000 patient complaints during a criminal investigation by the Department of Justice (1"The Tan Sheet" Aug. 19, 2002, p. 3)...
You may also be interested in...
An FDA task force will review the 13,000 ephedrine alkaloid patient complaint records Metabolife is releasing in response to publicity surrounding a criminal investigation into whether the company lied about its knowledge of adverse events
The China National Biotec Group has filed the first application in China for the broad use of a COVID-19 vaccine, days after the national regulatory agency released review guidelines for the conditional approval of such products.
More patent-related turbulence appears ahead for Novartis’s sacubitril/valsartan combination in India, with Torrent emerging as the new challenger. The companies are engaged in a legal battle and the Indian firm is also seeking a revocation of the patent on the star heart failure treatment.